597 related articles for article (PubMed ID: 27197529)
1. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
[TBL] [Abstract][Full Text] [Related]
2. Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide Variations.
Delsing Malmberg E; Rehammar A; Pereira MB; Abrahamsson J; Samuelsson T; Ståhlman S; Asp J; Tierens A; Palmqvist L; Kristiansson E; Fogelstrand L
J Mol Diagn; 2019 Jan; 21(1):149-162. PubMed ID: 30273780
[TBL] [Abstract][Full Text] [Related]
3. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.
Onecha E; Linares M; Rapado I; Ruiz-Heredia Y; Martinez-Sanchez P; Cedena T; Pratcorona M; Oteyza JP; Herrera P; Barragan E; Montesinos P; Vela JAG; Magro E; Anguita E; Figuera A; Riaza R; Martinez-Barranco P; Sanchez-Vega B; Nomdedeu J; Gallardo M; Martinez-Lopez J; Ayala R
Haematologica; 2019 Feb; 104(2):288-296. PubMed ID: 30093399
[TBL] [Abstract][Full Text] [Related]
4. Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.
Salipante SJ; Fromm JR; Shendure J; Wood BL; Wu D
Mod Pathol; 2014 Nov; 27(11):1438-46. PubMed ID: 24743218
[TBL] [Abstract][Full Text] [Related]
5. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
[TBL] [Abstract][Full Text] [Related]
6. Comparison of flow cytometry and next-generation sequencing in minimal residual disease monitoring of acute myeloid leukemia: One institute's practical clinical experience.
F McGowan P; D Hyter S; Cui W; Plummer RM; Godwin AK; Zhang D
Int J Lab Hematol; 2022 Feb; 44(1):118-126. PubMed ID: 34585519
[TBL] [Abstract][Full Text] [Related]
7. Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia.
Hirsch P; Tang R; Abermil N; Flandrin P; Moatti H; Favale F; Suner L; Lorre F; Marzac C; Fava F; Mamez AC; Lapusan S; Isnard F; Mohty M; Legrand O; Douay L; Bilhou-Nabera C; Delhommeau F
Haematologica; 2017 Jul; 102(7):1227-1237. PubMed ID: 28302711
[TBL] [Abstract][Full Text] [Related]
8. Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory.
Blombery P; Jones K; Doig K; Ryland G; McBean M; Thompson E; Yannakou CK; Westerman D
Arch Pathol Lab Med; 2018 May; 142(5):606-612. PubMed ID: 29425073
[TBL] [Abstract][Full Text] [Related]
9. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.
Luthra R; Patel KP; Reddy NG; Haghshenas V; Routbort MJ; Harmon MA; Barkoh BA; Kanagal-Shamanna R; Ravandi F; Cortes JE; Kantarjian HM; Medeiros LJ; Singh RR
Haematologica; 2014 Mar; 99(3):465-73. PubMed ID: 24142997
[TBL] [Abstract][Full Text] [Related]
10. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Jongen-Lavrencic M; Grob T; Hanekamp D; Kavelaars FG; Al Hinai A; Zeilemaker A; Erpelinck-Verschueren CAJ; Gradowska PL; Meijer R; Cloos J; Biemond BJ; Graux C; van Marwijk Kooy M; Manz MG; Pabst T; Passweg JR; Havelange V; Ossenkoppele GJ; Sanders MA; Schuurhuis GJ; Löwenberg B; Valk PJM
N Engl J Med; 2018 Mar; 378(13):1189-1199. PubMed ID: 29601269
[TBL] [Abstract][Full Text] [Related]
11. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
Pettersson L; Levéen P; Axler O; Dvorakova D; Juliusson G; Ehinger M
Genes Chromosomes Cancer; 2016 Oct; 55(10):750-66. PubMed ID: 27191933
[TBL] [Abstract][Full Text] [Related]
12. Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia.
Dillon LW; Hayati S; Roloff GW; Tunc I; Pirooznia M; Mitrofanova A; Hourigan CS
Haematologica; 2019 Feb; 104(2):297-304. PubMed ID: 30171026
[TBL] [Abstract][Full Text] [Related]
13. Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.
Yu T; Chi J; Wang L
Hematology; 2021 Dec; 26(1):848-859. PubMed ID: 34674615
[TBL] [Abstract][Full Text] [Related]
14. Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.
Hantel A; Stock W; Kosuri S
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):636-647. PubMed ID: 30006258
[TBL] [Abstract][Full Text] [Related]
15. Close correlation of copy number aberrations detected by next-generation sequencing with results from routine cytogenetics in acute myeloid leukemia.
Vosberg S; Herold T; Hartmann L; Neumann M; Opatz S; Metzeler KH; Schneider S; Graf A; Krebs S; Blum H; Baldus CD; Hiddemann W; Spiekermann K; Bohlander SK; Mansmann U; Greif PA
Genes Chromosomes Cancer; 2016 Jul; 55(7):553-67. PubMed ID: 27015608
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous detection of mutations and copy number variation of NPM1 in the acute myeloid leukemia using multiplex ligation-dependent probe amplification.
Marcinkowska-Swojak M; Handschuh L; Wojciechowski P; Goralski M; Tomaszewski K; Kazmierczak M; Lewandowski K; Komarnicki M; Blazewicz J; Figlerowicz M; Kozlowski P
Mutat Res; 2016 Apr; 786():14-26. PubMed ID: 26894557
[TBL] [Abstract][Full Text] [Related]
17. Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia.
Shiba N; Yoshida K; Shiraishi Y; Okuno Y; Yamato G; Hara Y; Nagata Y; Chiba K; Tanaka H; Terui K; Kato M; Park MJ; Ohki K; Shimada A; Takita J; Tomizawa D; Kudo K; Arakawa H; Adachi S; Taga T; Tawa A; Ito E; Horibe K; Sanada M; Miyano S; Ogawa S; Hayashi Y
Br J Haematol; 2016 Nov; 175(3):476-489. PubMed ID: 27470916
[TBL] [Abstract][Full Text] [Related]
18. Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing.
Ritterhouse LL; Parilla M; Zhen CJ; Wurst MN; Puranik R; Henderson CM; Joudeh NZ; Hartley MJ; Haridas R; Wanjari P; Furtado LV; Kadri S; Segal JP
Mol Diagn Ther; 2019 Dec; 23(6):791-802. PubMed ID: 31673932
[TBL] [Abstract][Full Text] [Related]
19. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
20. Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing.
Masetti R; Castelli I; Astolfi A; Bertuccio SN; Indio V; Togni M; Belotti T; Serravalle S; Tarantino G; Zecca M; Pigazzi M; Basso G; Pession A; Locatelli F
Oncotarget; 2016 Aug; 7(35):56746-56757. PubMed ID: 27462774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
